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Cytokine-based therapies against cancer 
are aimed to stimulate the host immune 
system and thus achieve therapeutic 
responses. To this end, interleukin-12 
(IL-12) has been proposed as a potential 
anticancer drug due to its immunostim-
ulatory capacities. However, the IL-12 
effect in preclinical and clinical settings 
is limited by the tumor-induced immune 
subversion. Tumors are heterogeneous 
tissues composed of a variety of cell types 
that participate in tangled interactions 
with one another. Some of these cells 
belong to the immune system and they 
abrogate effector antitumor responses. 
For instance, in a recent report in ref-
erence 1, we showed that mice bearing 
MC38 established tumors accumulate 
regulatory T cells (Treg) and myeloid-
derived suppressor cells (MDSC) in sec-
ondary lymphoid organs and tumors. 
Tumor MDSC displayed a monocytic 
and more differentiated phenotype due 
to the presence of tumor-derived factors, 
which induce their maturation toward 
tumor-infiltrating macrophages or den-
dritic cells.2
Colon cancer eradication  
after chemoimmunotherapy is associated  
with intratumoral emergence  
of proinflammatory myeloid cells
José Medina-Echeverz and Pedro Berraondo*
Division of Hepatology and Gene Therapy; Center for Applied Medical Research; University of Navarra; Pamplona, Navarra Spain
Key words: interleukin-12, cyclophosphamide, colorectal cancer, inflammatory myeloid cells
Abbreviations: CPA, cyclophosphamide; MDSC, myeloid-derived suppressor cell; Treg, regulatory T cell;  
IMC, inflammatory myeloid cell; IL-12, interleukin-12
*Correspondence to: Pedro Berraondo; Email: pberraondol@unav.es
Submitted: 09/09/11; Accepted: 09/09/11
http://dx.doi.org/10.4161/onci.1.1.18049
The modulation of the tumor micro-
environment might therefore be required 
for the therapeutic success of cytokine-
based therapies. Based on this hypothesis, 
we combined IL-12 gene delivery either 
with Treg depletion by anti-CD25 mAb 
or single low-dose cyclophosphamide 
(CPA) injection in established MC38 
tumor bearing mice. As expected due to 
tumor size, IL-12 monotherapy did not 
work. Anti-CD25 combination showed 
poor therapeutic success contrasting with 
CPA+IL-12, which induced tumor eradi-
cation in 70% of treated mice.
Further insight into the mechanism 
of action confirmed that IL-12 effect was 
counteracted by the tumor microenvi-
ronment, since CD3+ cells are retained 
at the tumor rim and tumor Treg and 
MDSC populations increase. This find-
ing strengthens our previous results in 
c-myc mice bearing spontaneous hepato-
carcinomas.3 Remarkably, CPA treatment 
efficiently infiltrated lymphocytes—espe-
cially activated MC38 tetramer-specific 
CD8+ T cells—within tumors when 
compared with anti-CD25. In fact, the 
antitumor effect of CPA in combination 
with IL-12 relies on CD8+ T cell infiltra-
tion, as depletion experiments confirmed. 
Surprisingly, both combined therapies 
significantly decreased Treg and mono-
cytic MDSC subsets within tumors, 
meaning that both treatments were able 
to modulate tumor immune suppressive 
populations. Strikingly, only CPA+IL-12 
combined treatment resulted in the occur-
rence of CD11b+ myeloid cells expressing 
high levels of Ly6C monocyte/macro-
phage lineage marker within the tumor 
bed. Giemsa staining and differential sur-
face expression of Ly6G and Ly6C among 
myeloid cells discerned among neutro-
phils and inflammatory monocytes/mac-
rophages; this heterogenous population 
was named inflammatory myeloid cells 
(IMC).
We noticed that the tumor micro-
environment plays an active role in the 
infiltration of IMC, since the kinetics in 
the tumor is different to that observed in 
spleen. In vitro experiments with isolated 
CD11b+ cells from mock- or CPA+IL-12 
treated established MC38 tumors 
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the tumor site is essential for eradication 
of MC38 established tumors by low-dose 
cyclophosphamide plus IL-12 treatment.
In conclusion, our recent report showed 
how tumor immune modulation followed 
by the enhancement of host immunity 
clearly affects the tumor site. In our case, 
both combinations of IL-12 either with 
anti-CD25 mAb or low-dose CPA resulted 
in a drastic reduction of tumor Treg 
and MDSC. However, only CPA+IL-12 
reflects an influx of innate immune cells 
within the tumor which led to a strong 
T
H
1 pro-inflammatory response, resulting 
in tumor rejection (Fig. 1). Our work cor-
relates tumor eradication with the transi-
tion from an immune suppressive tumor 
microenvironment toward an inflamma-
tory milieu. Although the rapid turnover 
of neutrophil and monocytic populations 
IFNγ by CD8+ T cells were higher in the 
presence of IMC than when compared 
with monocytic MDSC. Moreover, TGFβ 
did not affect the proliferation of CD4+ 
and CD8+ T cells when co-cultured with 
IMC, which was inhibited in the presence 
of monocytic MDSC. Altogether, IMC 
creates a suitable milieu to activate antitu-
mor T cell immunity at the bench.
To appreciate how important IMC 
generation is in supporting CPA+IL-12-
mediated tumor rejection, intratumoral 
depletion of granulocytes and monocytes 
was performed 24 h after giving CPA com-
bination. These mice were unable to reject 
MC38 solid tumors. In fact, in vivo IMC 
depletion led to a lack of lymphocyte infil-
tration within tumors, involving a dras-
tic reduction of tumor infiltrating CD4+ 
and CD8+ T cells. Thus, IMC upsurge at 
evidenced changes in the cytokine/che-
mokine secretion patterns. For instance, 
secretion of the immunosuppressive mol-
ecules interleukin 10 and nitric oxide in 
response to LPS was significantly higher 
in mock-treated monocytic MDSC than 
from CPA+IL-12 tumor IMC. Moreover, 
clear differences in the production of 
chemokines and cytokines by IMC 
and monocytic MDSC could be com-
pared with those between M1 and M2 
macrophages.4,5
Functional interactions with lympho-
cytes in vitro also reflected the inflam-
matory signature shown by tumor IMC. 
While monocytic MDSC induced conver-
sion of naive CD4+ T cells to FoxP3+ Treg, 
IMC did not promote this conversion. We 
also found that the proliferative response 
of CD4+ T cells and the production of 
Figure 1. Schematic representation of the effect of cyclophosphamide and interleukin-12 treatment on the tumor microenvironment. CPA, cyclophos-
phamide; MDSC, myeloid-derived suppressor cell; Treg, regulatory T cell; IMC, inflammatory myeloid cell; IL-12, interleukin-12.
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adds a degree of complexity when moni-
toring their occurrence in antitumor 
responses, compelling evidence is being 
obtained in both preclinical and clinical 
situations concerning how innate immune 
stimulation is pivotal for orchestrating 
tumor rejection.6-8 Therefore, forthcom-
ing clinical trials of immunotherapy 
should pay attention to the dynamics of 
the intratumoral innate immune system.
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